![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjNmUvgnEOPwv8WyJAUVgKF7H74TCC0LEfFIqd2de1RU8lQnqRCKoNPkVZ_W83oF8tDAF0wDCXEFAu92w0_cEY9qDc5ddtcoYME5MXl3nWov0N78mU6lorG1SlGCyWzd5PDKO2NZ2Cv95KZ/s320/INFI2021010720210127-719304.png)
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
http://www.priceseries.com/trade/INFI-Infinity-Pharmaceuticals-Inc-stock-gains-41-percent-a-Trade-Record-by-priceSeries-2021010720210127.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments